Clinical Trial Update: 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial is evaluating the combination of 177Lu-PSMA-617 with sipuleucel-T for metastatic castration-resistant prostate cancer, and it is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pluvicto (177Lu-PSMA-617) (lutetium-177 PSMA-617)
• Provenge (sipuleucel-T) (sipuleucel-T)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Status: RECRUITING